Diuretics Are Preferred Over Angiotensin II-Converting Enzyme Inhibitors For Initial Therapy of Uncomplicated Hypertension

American Journal of Kidney Diseases

Volumn 50, Issue 2, 2007, Pages 197-202

  Campese, Vito M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; LOSARTAN; PERINDOPRIL;

ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE TOLERANCE; HAZARD RATIO; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PATIENT SELECTION; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; HUMANS; HYPERTENSION; PEPTIDYL-DIPEPTIDASE A;

EID: 34447626616     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.06.005     Document Type: Article

References (28)

1. Tuck M.L., Sowers J., Dornfeld L., Kledzik G., and Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New Engl J Med 304 (1981) 930-933
2. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (2003) 2560-2572
3. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 277 (1997) 739-745
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
5. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
6. Hansson L., Zanchetti A., Carruthers S.G., et al., HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
7. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 362 (2003) 1527-1535
8. Wing L.M.H., Reid C.M., Ryan P., et al., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
9. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
10. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
11. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 1004-1010
12. Wilkins R.W. New drugs for the treatment of hypertension. Ann Intern Med 50 (1959) 1-10
13. Goldner M.G., Zarowitz H., and Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med 262 (1960) 403-405
14. Houston M.C. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 115 (1988) 640-656
15. Zillich A.J., Garg J., Basu S., Bakris G.L., and Carter B.L. Thiazide diuretics, potassium and the development of diabetes. A quantitative review. Hypertension 48 (2006) 219-224
16. Punzi H.A., and Punzi C.F. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. Curr Hypertens Rep 6 (2004) 106-110
17. Sierra C., and Ruilope L.M. New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial. J Renin Angiotensin Aldosterone Syst 4 (2003) 169-170
18. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
19. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 1401-1409
20. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., and Davis B.R. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 (2005) 29-35
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
22. Dahlöf B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366 (2005) 895-906
23. Staessen J.A., Thijs L., and Birkenhäger W.H. Noncardiovascular Illness as Barrier to Antihypertensive Treatment. Hypertension 46 (2005) 255-256
24. Moser M. The ASCOT Trial. Commentary. J Clin Hypertens 7 (2005) 748-750
25. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361 (2003) 1149-1158
26. Sever P., Dahlöf B., Poulter N., et al., ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 27 (2006) 2982-2988
27. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 (2003) 2560-2572
28. Cutler J.A. Thiazide-associated glucose abnormalities: Prognosis, etiology, and prevention. Is potassium balance the key?. Hypertension 48 (2006) 198